Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLEKHA8 shRNA is a gene-silencing tool designed to knock down the expression of the PLEKHA8 (Pleckstrin homology domain-containing family A member 8) gene, also known as FAPP2. PLEKHA8 is a Golgi-associated protein involved in lipid metabolism and transport, specifically binding to phosphatidylinositol 4-monophosphate (PI4P). In the context of T-cell acute lymphoblastic leukemia (T-ALL), PLEKHA8 is often overexpressed. Research using lentivirus-based shRNA systems has demonstrated that reducing PLEKHA8 levels inhibits T-ALL cell proliferation, induces cell cycle arrest in the sub-G1 phase, and promotes autophagy by altering PI4P distribution. This suggests PLEKHA8 as a potential therapeutic target for aggressive hematological malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PLEKHA8 shRNA.